Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.
Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy.
复制标题
尖端：局部重组神经生长因子用于治疗神经营养性角膜病生物学作为神经营养性角膜病的新疗法。
DOI：
10.1097/ico.0000000000002974
复制
发表时间：
2022-06-01
期刊：
影响因子：
2.8
通讯作者：
中科院分区：
文献类型：
--
作者：
Ophthalmologists find management of neurotrophic keratopathy (NK) challenging, as conventional therapy lacks efficacy and may result in permanent loss of vision. Recombinant nerve growth factor (rhNGF, Cenegermin) targets the underlying pathogenesis of NK by regenerating corneal nerves and healing the corneal epithelium through promotion of proliferation, maturing corneal epithelial cells. It has been approved as FDA-approved treatment for NK. Herein, the background, clinical trials and impact of rhNGF as the first neurotrophic factor for the restoration of corneal integrity, homeostasis and corneal nerve regeneration are discussed.
